



**SOLVE
ON.**

Incyte Announces Abstracts Accepted for Presentation at the 2019 ASCO Annual Meeting and the 24th Congress of EHA

May 16, 2019

WILMINGTON, Del.--(BUSINESS WIRE)--May 16, 2019-- Incyte Corporation (Nasdaq:INCY) announces that multiple abstracts highlighting data from its oncology portfolio will be presented at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 31-June 4, 2019, in Chicago, Illinois; and the 24th Congress of the European Hematology Association (EHA), to be held June 13-16, 2019, in Amsterdam, the Netherlands.

Abstracts accepted for presentation at ASCO feature genomic profiling data from Incyte's ongoing Phase 2 FIGHT-202 trial evaluating its selective fibroblast growth factor receptor (FGFR) inhibitor, pemigatinib, in patients with cholangiocarcinoma, as well as efficacy and safety data from the Novartis-sponsored GEOMETRY *mono-1* trial of capmatinib, the investigational selective MET inhibitor licensed to Novartis by Incyte. Additionally, data to be presented at EHA will showcase the continued study of Incyte's JAK1/JAK2 inhibitor, ruxolitinib, in myeloproliferative neoplasms (MPNs).

"Our presence at ASCO and EHA illustrates Incyte's ongoing commitment to discovering and developing therapeutic options that address significant unmet medical needs for patients," said Steven Stein, M.D., Chief Medical Officer, Incyte. "We are pleased to highlight new data on two investigational medicines – pemigatinib and capmatinib – that were discovered by Incyte scientists and for which we anticipate applications for initial U.S. regulatory approvals later this year, as well as data that furthers our understanding of the treatment of MPNs."

Key ASCO and EHA abstracts include:

ASCO Abstracts

Oral Presentation

Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase 2 GEOMETRY mono-1 study (Abstract #9004, oral abstract session)

- Monday, June 3, 2019, 9:12 – 9:24 a.m. CT, Hall B1

Poster Presentation

Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma (Abstract #4080, poster session)

- Monday, June 3, 2019, 8:00 – 11:00 a.m. CT, Hall A

EHA Abstracts

Poster Presentations

Impact of myeloproliferative neoplasms (MPNs) and perceptions of treatment goals amongst physicians and patients in 6 countries: an expansion of the MPN Landmark Survey(Abstract #PF681, poster presentation)

- Friday, June 14, 2019, 5:30 – 7:00 p.m. CEST, Poster area

Real-world safety data from a non-interventional long-term post authorization safety study of ruxolitinib in myelofibrosis (Abstract #PF679, poster presentation)

- Friday, June 14, 2019, 5:30 – 7:00 p.m. CEST, Poster area

Safety and efficacy of ruxolitinib (RUX) in patients with myelofibrosis (MF) and anemia (hemoglobin <10g/dL):Results at Week 24 of the REALISE trial (Abstract #PS1465, poster presentation)

- Saturday, June 15, 2019, 5:30 – 7:00 p.m. CEST, Poster area

For full session details and data presentation listings, please see the ASCO (<https://iplanner.asco.org/am2019>) and EHA (<https://learningcenter.ehaweb.org/eha>) online programs.

Where the use of compounds described herein is either investigational or being studied for (a) new use(s), efficacy and safety have not been established, and there is no guarantee that such compounds will become commercially available for the use(s) under investigation.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's website at www.incyte.com.

Follow @Incyte on Twitter at <https://twitter.com/Incyte>.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company's development pipeline and whether or when any development compounds will be approved for use in humans anywhere in the world, its presentation plans for the upcoming ASCO and EHA annual meetings and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company's development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ending March 31, 2019. Incyte disclaims any intent or obligation to update these forward-looking statements.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190516005849/en/>

Source: Incyte Corporation

Media

Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors

Michael Booth, DPhil
+1 302 498 5914
mbooth@incyte.com